Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on financial results, material corporate events, and key regulatory milestones for Syndax’s oncology-focused business.
Recent Forms 8-K filed by Syndax include items on quarterly and year-to-date financial results, where the company furnishes press releases and presentations summarizing revenue from Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), research and development spending, and operating expense trends. Other 8-K filings document significant events such as U.S. Food and Drug Administration approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, as well as board-level changes.
For investors analyzing SNDX, these SEC documents complement earnings press releases and conference call materials by providing standardized, time-stamped records of the company’s disclosures. They help clarify how Syndax reports collaboration revenue from its agreement with Incyte for Niktimvo, how it describes its cash position and funding horizon, and how it characterizes the impact of regulatory approvals on its business.
On Stock Titan, Syndax filings are updated as new documents are posted to EDGAR, and AI-powered tools can assist in navigating complex language, highlighting items related to product approvals, clinical milestones, financial condition, and governance. Users can review 8-Ks for material events, and, where available, refer to 10-K and 10-Q filings for broader discussions of risk factors, pipeline programs, and the company’s description of its commercial-stage biopharmaceutical operations.
Syndax Pharmaceuticals is a commercial-stage biopharma company focused on cancer and fibrotic diseases, now built around two FDA‑approved medicines and a broad development pipeline.
The company markets Revuforj (revumenib), a first‑in‑class oral menin inhibitor approved in the United States for relapsed or refractory acute leukemia with a KMT2A translocation and for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in patients one year and older who lack satisfactory alternatives. Revuforj is being studied across the acute leukemia treatment continuum in multiple Phase 1–3 trials, including pivotal frontline combinations with venetoclax, azacitidine and intensive chemotherapy, and early programs in myelofibrosis and minimal residual disease.
Niktimvo (axatilimab‑csfr), a first‑in‑class CSF‑1R‑blocking antibody, is approved for chronic graft‑versus‑host disease after at least two prior systemic therapies in adults and pediatric patients weighing at least 40 kg. It showed a 75% overall response rate at the approved dose in the AGAVE‑201 study and is being co‑commercialized with Incyte in the United States, with Incyte holding ex‑U.S. rights. Axatilimab is in clinical development for newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis.
The business is supported by multiple global license agreements for its core assets, extensive patent estates extending into the 2030s and 2040s, and a significant royalty financing with Royalty Pharma, which provided an upfront $350 million in exchange for a capped percentage of future U.S. axatilimab net sales.
Syndax Pharmaceuticals reported strong commercial growth for 2025 as it ramped launches of Revuforj and Niktimvo. Total revenue reached $68.7 million in the fourth quarter and $172.4 million for 2025, driven by Revuforj net revenue of $124.8 million and Niktimvo collaboration revenue of $42.4 million.
The company remains loss-making, with a 2025 net loss attributable to common stockholders of $285.4 million, or $3.29 per share, but narrowed its loss versus 2024. Cash, cash equivalents and short-term investments were $394.1 million as of December 31, 2025, supporting an R&D and SG&A expense outlook of about $400 million for 2026.
Management highlighted accelerating prescription trends, multiple late-stage trials for Revuforj across acute leukemia settings, and completion of enrollment in the Phase 2 IPF trial of axatilimab, with topline data expected in the fourth quarter of 2026 as it targets a path to profitability.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger reported a sale of common stock primarily to cover taxes. On 02/09/2026, he sold 17,159 shares of Syndax Pharmaceuticals common stock at a price of $21.028 per share.
The filing explains that this sale represents shares required to be sold to satisfy tax withholding obligations related to the vesting of restricted stock units, rather than a discretionary open-market sale of his full holdings. After this transaction, Metzger beneficially owned 491,690 shares of Syndax Pharmaceuticals common stock in direct ownership.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported a sale of common stock tied to tax withholding. On February 9, 2026, he sold 3,410 shares of Syndax common stock at $21.028 per share.
According to the filing, this sale represents shares required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary open-market sale. After this transaction, Goldan directly beneficially owns 140,429 shares of Syndax common stock.
Syndax Pharmaceuticals insider Michael A. Metzger filed a notice of proposed sale under Rule 144 to sell 17,159 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $360,826.32. The shares were acquired on 02/06/2026 via restricted stock vesting as compensation. The planned sale is expected around 02/09/2026 on the NASDAQ. Over the prior three months, Metzger sold 7,412 common shares for gross proceeds of $152,836.18, also reported in the filing.
Syndax Pharmaceuticals shareholder files notice to sell shares. A person named Keith A. Goldan filed a Form 144 covering the planned sale of 3,410 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of
The shares to be sold were acquired as restricted stock vesting on
STATE STREET CORPORATION reported a significant ownership stake in Syndax Pharmaceuticals Inc. common stock. As of 12/31/2025, it beneficially owned 4,596,552 shares, representing 5.3% of the company’s common stock.
State Street reported no sole voting or dispositive power, but shared voting power over 4,341,322 shares and shared dispositive power over 4,596,552 shares. The position is certified as being held in the ordinary course of business and not for influencing control of Syndax.
Syndax Pharmaceuticals Chief Executive Officer and director Michael A. Metzger reported multiple equity transactions. On February 4, 2026, he received 73,000 restricted stock units that vest in three equal annual installments, plus 144,600 performance-based RSUs whose payout depends on pre-set metrics. He was also granted stock options for 440,000 shares at an exercise price of $20.43 per share, vesting monthly over four years. On February 6, 2026, he sold 7,412 shares of common stock at $20.62 per share to cover tax withholding tied to RSU vesting, and after these transactions directly owned 508,849 common shares and 440,000 options.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported multiple equity transactions in early
On
On
Syndax Pharmaceuticals director Jennifer Jarrett received an equity award linked to 24,000 shares of common stock on February 4, 2026. The award is in the form of restricted stock units that vest one year from the grant date.
After this grant, she beneficially owns 114,000 shares of Syndax common stock. The underlying shares cannot be delivered, transferred, or sold until vesting and certain events such as separation from service, death, disability, or a change in control.